Hypoglycaemia Neonatal

43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)

Administration of a placebo solution (0.5 ml / kg)

43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)

Administration of a placebo solution (1 ml / kg)

43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)

Administration of 40% glucose in gel (0.5 ml / Kg)

43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).

Administration of 40% glucose in gel 1 ml / Kg)

Poliambulanza Foundation Hospital Institute

Prevention of Hypoglycaemia by Oral 40% Destrogel

Use of Oral 40% Destrogel to Prevent Hypoglycaemia in Late-term Births and SGA or LGA Term Newborns

To assess whether a single administration of Destrogel 40% micronutrient can reduce the incidence of hypoglycaemia in late term newborns and in SGA and LGA term infants (gestational age: 37-42 weeks).

To evaluate whether the administration of the 40% micronutrient Destrogel is able to decrease the incidence of the use of formula milk and the intravenous administration of 10% glucose solution in late term infants and in SGA and LGA term newborns (gestational age: 37-42 weeks), reducing artificial breastfeeding in favour of breastfeeding and also reducing the pain of the newborn during the execution of peripheral venous access for the administration of hypoglycaemia therapy.

Giuseppe De Bernando

Principal Investigator

Fondazione Poliambulanza Istituto Ospedaliero

Adult patients with GH deficiency due to a nonsecreting pituitary tumor

Adult patients with a nonsecreting pituitary tumor but without GH deficiency

hypopituitarism/vomiting

Prevention of Hypoglycaemia by Oral 40% Destrogel

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

The most complete medicinal herbs database backed by science